Fadraciclib is a small molecule commercialized by Cyclacel Pharmaceuticals, with a leading Phase II program in Peripheral T-Cell Lymphomas (PTCL). According to Globaldata, it is involved in 5 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Fadraciclib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Fadraciclib is expected to reach an annual total of $106 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fadraciclib Overview
CYC-065 is under development for the treatment of hematological malignancies including relapsed or refractory acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), myelodysplastic syndrome, relapsed and refractory chronic lymphocytic leukemia, multiple myelomas, diffuse large B-cell lymphoma, B-cell lymphoma, T-cell lymphoma (CTCL and PTCL) and solid tumors including laryngeal cancer, endometrial cancer, neuroblastoma, ovarian, pancreatic cancer, lung cancer, metastatic breast cancer, hormone receptor positive breast cancer, triple negative and HER2 negative breast cancer, hepatocellular carcinoma, colorectal cancer (including KRAS mutant), lymphomas and uterine cancers. It is a small molecule administered orally and intravenously. CYC065 is a potent derivative of seliciclib. It is a cell cycle kinase inhibitor (CDK 2 and CDK9). CYC065 targets the CDK/cyclin complexes. It was also under development for the treatment of inflammation in COVID-19 patients.
Cyclacel Pharmaceuticals Overview
Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. Cyclacel seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
The operating loss of the company was US$22.9 million in FY2021, compared to an operating loss of US$10.6 million in FY2020. The net loss of the company was US$18.9 million in FY2021, compared to a net loss of US$8.5 million in FY2020.
For a complete picture of Fadraciclib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Source link
#current #valuation #Cyclacel #Pharmaceuticalss #Fadraciclib
